Company Profile
Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. (hereinafter referred to as Tri-Prime) is a leading biopharmaceutical enterprise with a registered capital of RMB 110 million Yuan. It is specialized in research, development, production and sales of medical & biotechnological products, including genetic engineering drugs, genetic engineering vaccine and diagnostic reagent, and also carries out technology trade and technical consulting services related thereto.
Founded in 1992, Tri-Prime was co-founded by Dr. Hou Yunde, former vice president of the Chinese Academy of Engineering and Mr. Cheng Yongqing, who is one of China's first professional managers engaged in high-tech entrepreneurship and venture capital investment.
As the main product of Tri-Prime, Recombinant Human Interferon-α1b (Hapgen®) is China’s first genetic engineering Class Ⅰ new drug, with its own independent intellectual property rights. Used to treat various kinds of viral diseases and malignant tumors, Hapgen® has established its top notch brand position in China, and generated great economic and social benefits.
Tri-Prime has developed strong R&D capabilities and has undertaken a number of critical new drug development projects at the Beijing municipal level and state level. Since 2001, a post-doctoral research station has established in Tri-Prime and approved by the State Ministry of Personnel. Currently, Tri-Prime has more than 10 approved products with certificates for manufacturing and sales, and holds over 10 new candidate products in pre-clinical and clinical stage. In addition, Tri-Prime owns more than 40 invention patents from China, the US and other countries.